The Research Center for Bone and Stem Cells, Nanjing Medical University, Nanjing, China.
PLoS One. 2011 Feb 4;6(2):e16789. doi: 10.1371/journal.pone.0016789.
Human amniotic membrane-derived mesenchymal stem cells (hAMCs) have the potential to reduce heart and lung fibrosis, but whether could reduce liver fibrosis remains largely unknown.
METHODOLOGY/PRINCIPAL FINDINGS: Hepatic cirrhosis model was established by infusion of CCl₄ (1 ml/kg body weight twice a week for 8 weeks) in immunocompetent C57Bl/6J mice. hAMCs, isolated from term delivered placenta, were infused into the spleen at 4 weeks after mice were challenged with CCl₄. Control mice received only saline infusion. Animals were sacrificed at 4 weeks post-transplantation. Blood analysis was performed to evaluate alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Histological analysis of the livers for fibrosis, hepatic stellate cells activation, hepatocyte apoptosis, proliferation and senescence were performed. The donor cell engraftment was assessed using immunofluorescence and polymerase chain reaction. The areas of hepatic fibrosis were reduced (6.2%±2.1 vs. control 9.6%±1.7, p<0.05) and liver function parameters (ALT 539.6±545.1 U/dl, AST 589.7±342.8 U/dl,vs. control ALT 139.1±138.3 U/dl, p<0.05 and AST 212.3±110.7 U/dl, p<0.01) were markedly ameliorated in the hAMCs group compared to control group. The transplantation of hAMCs into liver-fibrotic mice suppressed activation of hepatic stellate cells, decreased hepatocyte apoptosis and promoted liver regeneration. More interesting, hepatocyte senescence was depressed significantly in hAMCs group compared to control group. Immunofluorescence and polymerase chain reaction revealed that hAMCs engraftment into host livers and expressed the hepatocyte-specific markers, human albumin and α-fetoproteinran.
CONCLUSIONS/SIGNIFICANCE: The transplantation of hAMCs significantly decreased the fibrosis formation and progression of CCl₄-induced cirrhosis, providing a new approach for the treatment of fibrotic liver disease.
人羊膜间充质干细胞(hAMCs)具有减轻心、肺纤维化的潜力,但能否减轻肝纤维化在很大程度上尚不清楚。
方法/主要发现:采用每周两次向免疫功能正常的 C57Bl/6J 小鼠腹腔内注射 CCl₄(1ml/kg 体重)8 周的方法建立肝硬化模型。在 CCl₄ 注射后 4 周,将分离自足月胎盘的 hAMCs 注入脾脏。对照组仅给予生理盐水输注。在移植后 4 周处死动物。通过检测丙氨酸转氨酶(ALT)和天门冬氨酸转氨酶(AST)评估血液分析。对肝脏纤维化、肝星状细胞激活、肝细胞凋亡、增殖和衰老进行组织学分析。通过免疫荧光和聚合酶链反应评估供体细胞的嵌合情况。肝纤维化面积减少(6.2%±2.1 比对照组 9.6%±1.7,p<0.05),肝功能参数(ALT 539.6±545.1 U/dl,AST 589.7±342.8 U/dl,比对照组 ALT 139.1±138.3 U/dl,p<0.05 和 AST 212.3±110.7 U/dl,p<0.01)在 hAMCs 组与对照组相比明显改善。hAMCs 移植到肝纤维化小鼠中抑制肝星状细胞激活,减少肝细胞凋亡,促进肝再生。更有趣的是,与对照组相比,hAMCs 组肝细胞衰老明显受到抑制。免疫荧光和聚合酶链反应显示 hAMCs 植入宿主肝脏并表达肝细胞特异性标志物,人白蛋白和α-胎蛋白。
结论/意义:hAMCs 移植可显著减少 CCl₄ 诱导的肝硬化的纤维化形成和进展,为治疗肝纤维化疾病提供了新方法。